Cambridge Cognition Patent - Combination Therapy for Schizophrenia
Summary
The USPTO granted Patent US12594270B2 to Cambridge Cognition Limited on April 7, 2026. The patent covers a combined therapy comprising alpha-7 nicotinic acetylcholine receptor activators with 5-HT3 receptor inhibitory activity combined with 5-HT3 receptor activators for treating schizophrenic disorders. The patent contains 21 claims and names Kiri Granger and Jennifer Barnett as inventors.
What changed
USPTO issued Patent US12594270B2 to Cambridge Cognition Limited for a combination therapy method of treating schizophrenic disorders. The patent claims a regimen combining one or more alpha-7 nicotinic acetylcholine receptor activators that also possess 5-HT3 receptor inhibitory activity with one or more 5-HT3 receptor activators. The patent application was filed on October 21, 2020, under Application No. 17755084.
For pharmaceutical companies and researchers in CNS therapeutics, this patent establishes intellectual property protection around a novel dual-mechanism approach to schizophrenia treatment. Cambridge Cognition Limited now holds exclusive rights to commercialize this combination therapy, which may impact competitive positioning in the antipsychotic drug development space.
What to do next
- Monitor for potential licensing opportunities
- Review patent claims for overlap with existing drug development programs
- Track expiration date for portfolio management
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Schizophrenic disorder treatment using combination therapy
Grant US12594270B2 Kind: B2 Apr 07, 2026
Assignee
Cambridge Cognition Limited
Inventors
Kiri Granger, Jennifer Barnett
Abstract
The present specification disclose a combined therapy comprising one or more activators of an alpha-7 nicotinic acetylcholine receptor activity having 5-HT3 receptor inhibitory activity and one or more activators of 5-HT3 receptor activity for use in treating a schizophrenic disorder as well as methods of treating a schizophrenic disorder by administering a combined therapy comprising one or more activators of an alpha-7 nicotinic acetylcholine receptor activity having 5-HT3 receptor inhibitory activity and one or more activators of 5-HT3 receptor activity.
CPC Classifications
A61P 25/18 A61K 31/46 A61K 31/465 A61K 31/55 A61K 45/06
Filing Date
2020-10-21
Application No.
17755084
Claims
21
Named provisions
Related changes
Get daily alerts for ChangeBridge: Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Grants - Therapeutics (A61P) publishes new changes.